Q1 EPS Estimate for Mirum Pharmaceuticals Reduced by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Thursday, February 26th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $130.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $2.47 EPS, FY2029 earnings at $4.59 EPS and FY2030 earnings at $7.07 EPS.

MIRM has been the topic of several other research reports. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Evercore reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, February 26th. Citizens Jmp cut their price target on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 26th. Royal Bank Of Canada decreased their price objective on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $114.92.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $87.80 on Monday. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of -182.91 and a beta of 0.52. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $109.28. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. The stock has a 50-day moving average price of $93.74 and a 200 day moving average price of $79.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same period last year, the business posted $1.00 earnings per share. The firm’s quarterly revenue was up 49.8% on a year-over-year basis.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Cullen Frost Bankers Inc. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $30,000. MCF Advisors LLC grew its holdings in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. CIBC Private Wealth Group LLC bought a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. Finally, Quantbot Technologies LP acquired a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $33,000.

Insider Buying and Selling

In other news, Director Patrick J. Heron bought 131,425 shares of the stock in a transaction on Friday, January 23rd. The stock was purchased at an average price of $68.48 per share, for a total transaction of $8,999,984.00. Following the acquisition, the director owned 459,010 shares in the company, valued at approximately $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Peter Radovich sold 3,143 shares of the business’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the sale, the chief operating officer owned 23,286 shares in the company, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.